Allahabad High Court : Deceased Farmer’s Odd Jobs Don’t Bar Family from Scheme Benefits || Secured Creditors' Dues Take Priority Over Govt Claims: Allahabad HC on SARFAESI & RDB Acts || Daughter Can’t Claim Mitakshara Father’s Property if He Died Pre-1956 & Son Survives: HC || Gujarat High Court: Sessions Court Can’t Suspend Sentence Just to Allow Revision Filing || Delhi High Court: Non-Combat Security Roles Crucial; Minor Lapse Risks National Safety || Punjab & Haryana HC: Allegation of Harassment Alone Insufficient to Prove Abetment to Suicide || Orissa HC: Directors Liable under S.138 NI Act Despite Company’s Insolvency || Bombay HC: GST Return Details of Company Exempt from Disclosure under RTI Act || Chhattisgarh HC: Timely Appointment of Electronic Evidence Examiners Vital in Cyber Crime Probes || Bombay HC: GST Return Details of Company Exempt from Disclosure under RTI Act

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :